{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T19:25:40Z","timestamp":1759778740395,"version":"3.44.0"},"reference-count":118,"publisher":"Elsevier BV","issue":"7-8","license":[{"start":{"date-parts":[[2014,5,1]],"date-time":"2014-05-01T00:00:00Z","timestamp":1398902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,5,1]],"date-time":"2014-05-01T00:00:00Z","timestamp":1398902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Biochemistry"],"published-print":{"date-parts":[[2014,5]]},"DOI":"10.1016\/j.clinbiochem.2014.03.005","type":"journal-article","created":{"date-parts":[[2014,3,22]],"date-time":"2014-03-22T19:18:24Z","timestamp":1395515904000},"page":"516-528","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Efficacy and safety of prasugrel in acute coronary syndrome patients"],"prefix":"10.1016","volume":"47","author":[{"given":"Radu M.","family":"Nanau","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Faustine","family":"Delzor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuela G.","family":"Neuman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"author":"World Health Organization","key":"10.1016\/j.clinbiochem.2014.03.005_bb0005"},{"key":"10.1016\/j.clinbiochem.2014.03.005_bb0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18433\/J3MP4Z","article-title":"Efficacy and safety of platelet inhibitors","volume":"16","author":"Binazon","year":"2013","journal-title":"J Pharm Pharm Sci"},{"key":"10.1016\/j.clinbiochem.2014.03.005_bb0015","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1136\/hrt.2004.038679","article-title":"British Cardiac Society Working Group on the definition of myocardial infarction","volume":"90","author":"Fox","year":"2004","journal-title":"Heart"},{"key":"10.1016\/j.clinbiochem.2014.03.005_bb0020","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1111\/j.1365-2125.2011.03999.x","article-title":"Anti-platelet therapy: ADP receptor antagonists","volume":"72","author":"Wijeyeratne","year":"2011","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.clinbiochem.2014.03.005_bb0025","first-page":"83","article-title":"Results of the Ticlid or Plavix Post-Stents (TOPPS) trial: do they justify the switch from ticlopidine to clopidogrel after coronary stent placement?","volume":"1","author":"Berger","year":"2000","journal-title":"Curr Control Trials Cardiovasc Med"},{"key":"10.1016\/j.clinbiochem.2014.03.005_bb0030","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinbiochem.2014.03.005_bb0035","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0140-6736(09)62191-7","article-title":"Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study","volume":"375","author":"Cannon","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.clinbiochem.2014.03.005_bb0040","doi-asserted-by":"crossref","first-page":"3366","DOI":"10.1161\/CIRCULATIONAHA.104.502815","article-title":"Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial","volume":"111","author":"Wiviott","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.clinbiochem.2014.03.005_bb0045","doi-asserted-by":"crossref","first-page":"2923","DOI":"10.1161\/CIRCULATIONAHA.107.740324","volume":"116","author":"Wiviott","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.clinbiochem.2014.03.005_bb0050","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1016\/j.jacc.2012.02.026","volume":"59","author":"Trenk","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.clinbiochem.2014.03.005_bb0055","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1056\/NEJMoa1205512","article-title":"Prasugrel versus clopidogrel for acute coronary syndromes without revascularization","volume":"367","author":"Roe","year":"2012","journal-title":"N Engl J Med"},{"author":"FDA","key":"10.1016\/j.clinbiochem.2014.03.005_bb0060"},{"key":"10.1016\/j.clinbiochem.2014.03.005_bb0070","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/S0002-9343(02)01322-0","article-title":"Peripheral edema","volume":"113","author":"Cho","year":"2002","journal-title":"Am J Med"},{"key":"10.1016\/j.clinbiochem.2014.03.005_bb0075","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1016\/j.amjcard.2008.07.063","article-title":"Impact of \u201cnuisance\u201d bleeding on clopidogrel compliance in patients undergoing intracoronary drug-eluting stent implantation","volume":"102","author":"Roy","year":"2008","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.clinbiochem.2014.03.005_bb0080","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1093\/eurheartj\/ehm545","article-title":"Prasugrel achieves greater and faster P2Y12 receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease","volume":"29","author":"Wallentin","year":"2008","journal-title":"Eur Heart J"},{"key":"10.1016\/j.clinbiochem.2014.03.005_bb0085","doi-asserted-by":"crossref","first-page":"2681","DOI":"10.1161\/CIRCULATIONAHA.110.002683","volume":"123","author":"Hochholzer","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.clinbiochem.2014.03.005_bb0090","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.ahj.2006.04.012","volume":"152","author":"Wiviott","year":"2006","journal-title":"Am Heart J"},{"author":"FDA","key":"10.1016\/j.clinbiochem.2014.03.005_bb0095"},{"key":"10.1016\/j.clinbiochem.2014.03.005_bb0100","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/FJC.0b013e318031301b","article-title":"Dose-dependent inhibition of human platelet aggregation by prasugrel and its interaction with aspirin in healthy subjects","volume":"49","author":"Jakubowski","year":"2007","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.clinbiochem.2014.03.005_bb0105","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1007\/s11940-009-0049-x","article-title":"Antiplatelet therapy for prevention of recurrent stroke","volume":"11","author":"Badruddin","year":"2009","journal-title":"Curr Treat Options Neurol"},{"key":"10.1016\/j.clinbiochem.2014.03.005_bb0110","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1136\/neurintsurg-2012-010334","article-title":"Hemorrhagic complications after prasugrel (Effient) therapy for vascular neurointerventional procedures","volume":"5","author":"Akbari","year":"2013","journal-title":"J Neurointerv Surg"},{"key":"10.1016\/j.clinbiochem.2014.03.005_bb0115","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1136\/neurintsurg-2012-010302","article-title":"Prasugrel is effective and safe for neurointerventional procedures","volume":"5","author":"Stetler","year":"2013","journal-title":"J Neurointerv Surg"},{"key":"10.1016\/j.clinbiochem.2014.03.005_bb0120","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.2169\/internalmedicine.48.2031","article-title":"Upper gastrointestinal bleeding in patients receiving dual antiplatelet therapy after coronary stenting","volume":"48","author":"Yasuda","year":"2009","journal-title":"Intern Med"},{"key":"10.1016\/j.clinbiochem.2014.03.005_bb0125","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1161\/CIRCULATIONAHA.109.921502","article-title":"Prasugrel","volume":"122","author":"Wiviott","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.clinbiochem.2014.03.005_bb0130","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1055\/s-0030-1256317","article-title":"Endoscopy and antiplatelet agents. European Society of Gastrointestinal Endoscopy (ESGE) guideline","volume":"43","author":"Bousti\u00e8re","year":"2011","journal-title":"Endoscopy"},{"key":"10.1016\/j.clinbiochem.2014.03.005_bb0135","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1111\/j.1440-1746.2012.07085.x","article-title":"New look at antiplatelet agent-related peptic ulcer: an update of prevention and treatment","volume":"27","author":"Hsu","year":"2012","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.clinbiochem.2014.03.005_bb0140","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1016\/j.amjcard.2011.07.038","article-title":"Rate of nuisance bleedings and impact on compliance to prasugrel in acute coronary syndromes","volume":"108","author":"Armero","year":"2011","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.clinbiochem.2014.03.005_bb0145","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.amjcard.2011.08.034","article-title":"Residual platelet reactivity, bleedings, and adherence to treatment in patients having coronary stent implantation treated with prasugrel","volume":"109","author":"Parodi","year":"2012","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.clinbiochem.2014.03.005_bb0150","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1093\/eurheartj\/ehn362","article-title":"Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial","volume":"29","author":"Murphy","year":"2008","journal-title":"Eur Heart J"},{"key":"10.1016\/j.clinbiochem.2014.03.005_bb0155","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1001\/archinternmed.2010.154","article-title":"Prasugrel as a potential cancer promoter: review of the unpublished data","volume":"170","author":"Floyd","year":"2010","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.clinbiochem.2014.03.005_bb0160","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1038\/aps.2012.120","article-title":"Pharmacokinetics and pharmacodynamics of single and multiple doses of prasugrel in healthy native Chinese subjects","volume":"33","author":"Cui","year":"2012","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.clinbiochem.2014.03.005_bb0165","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.clinthera.2010.02.015","article-title":"Pharmacodynamics and pharmacokinetics of single doses of prasugrel 30mg and clopidogrel 300mg in healthy Chinese and white volunteers: an open-label trial","volume":"32","author":"Small","year":"2010","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinbiochem.2014.03.005_bb0170","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1097\/FJC.0b013e318290d9e1","article-title":"Pharmacokinetic and pharmacodynamic effects of prasugrel in healthy Korean males","volume":"62","author":"Yu","year":"2013","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.clinbiochem.2014.03.005_bb0175","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1093\/eurheartj\/ehp159","article-title":"Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial","volume":"30","author":"Michelson","year":"2009","journal-title":"Eur Heart J"},{"key":"10.1016\/j.clinbiochem.2014.03.005_bb0180","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1055\/s-0032-1301417","article-title":"High platelet reactivity and antiplatelet therapy resistance","volume":"38","author":"Linden","year":"2012","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.clinbiochem.2014.03.005_bb0185","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1160\/TH13-03-0203","article-title":"Identification of poor response to P2Y12 inhibitors in ACS patients with a new ELISA-based vasodilator-associated stimulated phosphoprotein (VASP) phosphorylation assay","volume":"110","author":"Abtan","year":"2013","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.clinbiochem.2014.03.005_bb0190","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1161\/CIRCULATIONAHA.107.696732","article-title":"Bedside evaluation of thienopyridine antiplatelet therapy","volume":"119","author":"Price","year":"2009","journal-title":"Circulation"},{"author":"Perry","key":"10.1016\/j.clinbiochem.2014.03.005_bb0195"},{"key":"10.1016\/j.clinbiochem.2014.03.005_bb0200","doi-asserted-by":"crossref","first-page":"4N","DOI":"10.1016\/j.amjcard.2006.09.008","article-title":"Current options in platelet function testing","volume":"98","author":"Michelson","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.clinbiochem.2014.03.005_bb0205","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.thromres.2006.01.019","article-title":"Monitoring platelet inhibition after clopidogrel with the VerifyNow-P2Y12(R) rapid analyzer: the VERIfy Thrombosis risk ASsessment (VERITAS) study","volume":"119","author":"Malinin","year":"2007","journal-title":"Thromb Res"},{"key":"10.1016\/j.clinbiochem.2014.03.005_bb0210","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/j.1538-7836.2004.01063.x","article-title":"Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases","volume":"3","author":"Aleil","year":"2005","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.clinbiochem.2014.03.005_bb0215","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1016\/j.thromres.2013.04.030","article-title":"Platelet reactivity evaluated with the VASP assay following ticagrelor loading dose in acute coronary syndrome patients undergoing percutaneous coronary intervention","volume":"132","author":"Laine","year":"2013","journal-title":"Thromb Res"},{"key":"10.1016\/j.clinbiochem.2014.03.005_bb0220","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1001\/jama.2012.17312","article-title":"Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy","volume":"308","author":"Gurbel","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.clinbiochem.2014.03.005_bb0225","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.jacc.2013.05.023","article-title":"Prasugrel 5mg in the Very Elderly Attenuates Platelet Inhibition But Maintains Noninferiority to Prasugrel 10mg in Nonelderly Patients: the GENERATIONS trial, a pharmacodynamic and pharmacokinetic study in stable coronary artery disease patients","volume":"62","author":"Erlinge","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.clinbiochem.2014.03.005_bb0230","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1160\/TH11-03-0202","article-title":"Prevalence of poor biological response to clopidogrel: a systematic review","volume":"107","author":"Mallouk","year":"2012","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.clinbiochem.2014.03.005_bb0235","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.jacc.2010.04.047","article-title":"Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate","volume":"56","author":"Bonello","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.clinbiochem.2014.03.005_bb0240","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1016\/j.jacc.2013.07.101","article-title":"Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding","volume":"62","author":"Tantry","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.clinbiochem.2014.03.005_bb0245","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1111\/j.1538-7836.2012.04875.x","article-title":"Relationship between post-treatment platelet reactivity and ischemic and bleeding events at 1-year follow-up in patients receiving prasugrel","volume":"10","author":"Bonello","year":"2012","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.clinbiochem.2014.03.005_bb0250","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.tox.2013.03.002","article-title":"Toxicity of thienopyridines on human neutrophil granulocytes and lymphocytes","volume":"308","author":"Maseneni","year":"2013","journal-title":"Toxicology"},{"key":"10.1016\/j.clinbiochem.2014.03.005_bb0255","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1124\/jpet.112.195883","article-title":"Prasugrel metabolites inhibit neutrophil functions","volume":"344","author":"Liverani","year":"2013","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.clinbiochem.2014.03.005_bb0260","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1056\/NEJMra020528","article-title":"Thrombotic microangiopathies","volume":"347","author":"Moake","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinbiochem.2014.03.005_bb0265","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1055\/s-0032-1328894","article-title":"Ticlopidine-, clopidogrel-, and prasugrel-associated thrombotic thrombocytopenic purpura: a 20-year review from the Southern Network on Adverse Reactions (SONAR)","volume":"38","author":"Jacob","year":"2012","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.clinbiochem.2014.03.005_bb0270","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0009-9120(00)00146-6","article-title":"A novel lymphocyte toxicity assay to assess drug hypersensitivity syndromes","volume":"33","author":"Neuman","year":"2000","journal-title":"Clin Biochem"},{"key":"10.1016\/j.clinbiochem.2014.03.005_bb0275","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1345\/aph.1R062","article-title":"Prasugrel-induced rash","volume":"46","author":"Deshmukh","year":"2012","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.clinbiochem.2014.03.005_bb0280","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.anai.2011.11.005","article-title":"Desensitization to prasugrel: cardiology's increased need for allergy consultation","volume":"108","author":"Mutnick","year":"2012","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.clinbiochem.2014.03.005_bb0285","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.1016\/j.ijcard.2011.09.051","article-title":"Allergic reaction to prasugrel and cross-reactivity with clopidogrel","volume":"157","author":"Raccah","year":"2012","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.clinbiochem.2014.03.005_bb0290","doi-asserted-by":"crossref","first-page":"P121","DOI":"10.1186\/1939-4551-6-S1-P121","article-title":"Allergic diseases of the skin and drug allergies\u20142036. Exanthematous drug eruption to prasugrel: a case report","volume":"6","author":"Buddiga","year":"2013","journal-title":"World Allergy Organ J"},{"key":"10.1016\/j.clinbiochem.2014.03.005_bb0295","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.aprim.2012.09.011","article-title":"To enlighten and to dazzle: a case of an inadequate prescription of prasugrel with an adverse reaction of urticarial","volume":"45","author":"B\u00e1ez-Montiel","year":"2013","journal-title":"Aten Primaria"},{"key":"10.1016\/j.clinbiochem.2014.03.005_bb0300","doi-asserted-by":"crossref","first-page":"207","DOI":"10.2165\/11209640-000000000-00000","article-title":"Prasugrel: a guide to its use in patients with acute coronary syndromes undergoing percutaneous coronary intervention in the US","volume":"12","author":"Lyseng-Williamson","year":"2012","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.clinbiochem.2014.03.005_bb0305","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1111\/j.1365-2710.2009.01067.x","article-title":"Pharmacokinetics and pharmacodynamics of prasugrel in subjects with moderate liver disease","volume":"34","author":"Small","year":"2009","journal-title":"J Clin Pharm Ther"},{"key":"10.1016\/j.clinbiochem.2014.03.005_bb0310","first-page":"38","article-title":"Efient\u00ae(prasugrel): a new antiplatelet agent","volume":"79","author":"van Schoor","year":"2011","journal-title":"SA Pharm J"},{"key":"10.1016\/j.clinbiochem.2014.03.005_bb0315","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.ejim.2013.01.021","article-title":"Improving the use of direct oral anticoagulants in atrial fibrillation","volume":"24","author":"Di Minno","year":"2013","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.clinbiochem.2014.03.005_bb0320","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.jjcc.2011.03.002","article-title":"Current status and prospects of antiplatelet therapy in percutaneous coronary intervention in Japan: focus onadenosine diphosphate receptor inhibitors","volume":"58","author":"Ogawa","year":"2011","journal-title":"J Cardiol"},{"key":"10.1016\/j.clinbiochem.2014.03.005_bb0325","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.recesp.2011.11.011","article-title":"Management of a hypersensitivity reaction to thienopyridines: prasugrel-induced fever and hepatitis resolved after switching to clopidogrel","volume":"65","author":"Fern\u00e1ndez-Ruiz","year":"2012","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"key":"10.1016\/j.clinbiochem.2014.03.005_bb0330","doi-asserted-by":"crossref","first-page":"e69093","DOI":"10.1371\/journal.pone.0069093","article-title":"Erosive arthritis and hepatic granuloma formation induced by peptidoglycan polysaccharide in rats is aggravated by prasugrel treatment","volume":"8","author":"Garcia","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.clinbiochem.2014.03.005_bb0335","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.jacc.2011.04.017","article-title":"High on-treatment platelet reactivity after prasugrel loading dose and cardiovascular events after percutaneous coronary intervention in acute coronary syndromes","volume":"58","author":"Bonello","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.clinbiochem.2014.03.005_bb0340","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1111\/j.1538-7836.2011.04217.x","article-title":"Contribution of the P2Y12 receptor-mediated pathway to platelet hyperreactivity in hypercholesterolemia","volume":"9","author":"Nagy","year":"2011","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.clinbiochem.2014.03.005_bb0345","doi-asserted-by":"crossref","first-page":"510","DOI":"10.3111\/13696998.2013.768998","article-title":"Prasugrel vs clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a model-based cost-effectiveness analysis for Germany, Sweden, the Netherlands, and Turkey","volume":"16","author":"Davies","year":"2013","journal-title":"J Med Econ"},{"key":"10.1016\/j.clinbiochem.2014.03.005_bb0350","doi-asserted-by":"crossref","DOI":"10.1097\/MJT.0b013e31828fdb1c","article-title":"Fatal sepsis and systemic inflammatory response syndrome after off-label prasugrel: a case report","author":"Serebruany","year":"2014","journal-title":"Am J Ther"},{"key":"10.1016\/j.clinbiochem.2014.03.005_bb0355","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1042\/CS20120194","article-title":"Effects of prasugrel on platelet inhibition during systemic endotoxaemia: a randomized controlled trial","volume":"123","author":"Spiel","year":"2012","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.clinbiochem.2014.03.005_bb0360","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1160\/TH12-03-0180","article-title":"Viewpoint: reversible nature of platelet binding causing transfusion-related acute lung injury (TRALI) syndrome may explain dyspnea after ticagrelor and elinogrel","volume":"108","author":"Serebruany","year":"2012","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.clinbiochem.2014.03.005_bb0365","doi-asserted-by":"crossref","first-page":"4048","DOI":"10.3748\/wjg.v17.i35.4048","article-title":"Esophageal mucosal lesion with low-dose aspirin and prasugrel mimics malignancy: a case report","volume":"17","author":"Ma","year":"2011","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.clinbiochem.2014.03.005_bb0370","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1111\/j.1742-7843.2012.00932.x","article-title":"Pharmacokinetic interaction between prasugrel and ritonavir in healthy volunteers","volume":"112","author":"Ancrenaz","year":"2013","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1016\/j.clinbiochem.2014.03.005_bb0375","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1592\/phco.28.12.1483","article-title":"Effect of atorvastatin on the pharmacokinetics and pharmacodynamics of prasugreland clopidogrel in healthy subjects","volume":"28","author":"Farid","year":"2008","journal-title":"Pharmacotherapy"},{"author":"European Medicines Agency","key":"10.1016\/j.clinbiochem.2014.03.005_bb0380"},{"key":"10.1016\/j.clinbiochem.2014.03.005_bb0385","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/S0140-6736(09)61525-7","article-title":"Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials","volume":"374","author":"O'Donoghue","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.clinbiochem.2014.03.005_bb0390","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/nrcardio.2011.128","article-title":"Managing adverse effects and drug\u2013drug interactions of antiplatelet agents","volume":"8","author":"Kalyanasundaram","year":"2011","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.clinbiochem.2014.03.005_bb0395","doi-asserted-by":"crossref","first-page":"e174","DOI":"10.1111\/j.1755-5922.2011.00263.x","article-title":"TRITON and beyond: new insights into the profile of prasugrel","volume":"30","author":"Jakubowski","year":"2012","journal-title":"Cardiovasc Ther"},{"key":"10.1016\/j.clinbiochem.2014.03.005_bb0400","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1007\/s12265-012-9442-z","article-title":"CYP-mediated pharmacologic interference with optimal platelet inhibition","volume":"6","author":"Cuisset","year":"2013","journal-title":"J Cardiovasc Transl Res"},{"key":"10.1016\/j.clinbiochem.2014.03.005_bb0405","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1038\/sj.clpt.6100139","article-title":"Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently","volume":"81","author":"Farid","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clinbiochem.2014.03.005_bb0410","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1177\/0091270009343005","article-title":"Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans","volume":"50","author":"Farid","year":"2010","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.clinbiochem.2014.03.005_bb0415","doi-asserted-by":"crossref","first-page":"777","DOI":"10.2165\/11537820-000000000-00000","article-title":"Effect of intrinsic and extrinsic factors on the clinical pharmacokinetics and pharmacodynamics of prasugrel","volume":"49","author":"Small","year":"2010","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.clinbiochem.2014.03.005_bb0420","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1002\/bdd.1795","article-title":"Differential inhibitory effects of proton pump inhibitors on the metabolism and antiplatelet activities of clopidogrel and prasugrel","volume":"33","author":"Chen","year":"2012","journal-title":"Biopharm Drug Dispos"},{"author":"Apotex Corp.","key":"10.1016\/j.clinbiochem.2014.03.005_bb0425"},{"key":"10.1016\/j.clinbiochem.2014.03.005_bb0430","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1177\/0091270008315310","article-title":"Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel","volume":"48","author":"Small","year":"2008","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.clinbiochem.2014.03.005_bb0435","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/j.ijcard.2013.01.042","article-title":"Smoking and prasugrel","volume":"168","author":"Ye","year":"2013","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.clinbiochem.2014.03.005_bb0440","doi-asserted-by":"crossref","DOI":"10.1016\/j.ahj.2012.06.005","article-title":"Prior smoking status, clinical outcomes, and the comparison of ticagrelor with clopidogrel in acute coronary syndromes-insights from the PLATelet inhibition and patient Outcomes (PLATO) trial","volume":"164","author":"Cornel","year":"2012","journal-title":"Am Heart J"},{"key":"10.1016\/j.clinbiochem.2014.03.005_bb0445","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.ahj.2011.06.005","article-title":"Impact of smoking on antiplatelet effect of clopidogrel and prasugrel after loading dose and on maintenance therapy","volume":"162","author":"Hochholzer","year":"2011","journal-title":"Am Heart J"},{"key":"10.1016\/j.clinbiochem.2014.03.005_bb0450","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.jacc.2013.03.037","article-title":"The Influence of Smoking Status on the Pharmacokinetics and Pharmacodynamics of Clopidogrel and Prasugrel: the PARADOX study","volume":"62","author":"Gurbel","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.clinbiochem.2014.03.005_bb0455","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.ahj.2012.12.024","article-title":"Thienopyridine efficacy and cigarette smoking status","volume":"165","author":"Bliden","year":"2013","journal-title":"Am Heart J"},{"key":"10.1016\/j.clinbiochem.2014.03.005_bb0460","doi-asserted-by":"crossref","first-page":"412","DOI":"10.2133\/dmpk.23.412","article-title":"Comparison of human cytochrome P450 inhibition by the thienopyridines prasugrel, clopidogrel, and ticlopidine","volume":"23","author":"Hagihara","year":"2008","journal-title":"Drug Metab Pharmacokinet"},{"author":"eVIDAL","key":"10.1016\/j.clinbiochem.2014.03.005_bb0465"},{"author":"FDA","key":"10.1016\/j.clinbiochem.2014.03.005_bb0470"},{"key":"10.1016\/j.clinbiochem.2014.03.005_bb0475","article-title":"Excess of solid cancers after prasugrel: the Food and Drug Administration outlook","author":"Serebruany","year":"2014","journal-title":"Am J Ther"},{"key":"10.1016\/j.clinbiochem.2014.03.005_bb0480","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/j.1472-8206.2009.00710.x","article-title":"Aggressive chronic platelet inhibition with prasugrel and increased cancer risks: revising oral antiplatelet regimens?","volume":"23","author":"Serebruany","year":"2009","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.clinbiochem.2014.03.005_bb0485","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ahj.2011.04.015","article-title":"Bleeding, mortality, and antiplatelet therapy: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial","volume":"162","author":"Berger","year":"2011","journal-title":"Am Heart J"},{"key":"10.1016\/j.clinbiochem.2014.03.005_bb0490","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1159\/000346382","article-title":"Unclassified pleomorphic and spindle cell pulmonary neoplasm with brain metastases after prasugrel","volume":"124","author":"Serebruany","year":"2013","journal-title":"Cardiology"},{"key":"10.1016\/j.clinbiochem.2014.03.005_bb0495","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.ejim.2013.01.017","article-title":"The platelet\u2013cancer loop","volume":"24","author":"Goubran","year":"2013","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.clinbiochem.2014.03.005_bb0500","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1177\/1091581812445073","article-title":"Nonclinical assessment of carcinogenic risk and tumor growth enhancement potential of prasugrel, a platelet-inhibiting therapeutic agent","volume":"31","author":"Buckley","year":"2012","journal-title":"Int J Toxicol"},{"key":"10.1016\/j.clinbiochem.2014.03.005_bb0505","doi-asserted-by":"crossref","first-page":"5940","DOI":"10.1158\/0008-5472.CAN-06-4682","article-title":"Platelet factor-4 variant chemokine CXCL4L1 inhibits melanoma and lung carcinoma growth and metastasis by preventing angiogenesis","volume":"67","author":"Struyf","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.clinbiochem.2014.03.005_bb0510","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/0002-8703(85)90632-5","article-title":"Intracoronary platelet activation in ischemic heart disease: effects of ticlopidine","volume":"109","author":"Ugarte","year":"1985","journal-title":"Am Heart J"},{"key":"10.1016\/j.clinbiochem.2014.03.005_bb0515","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1161\/01.CIR.0000085163.21752.0A","article-title":"Platelet\/endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor sertraline after acute coronary events: the Sertraline AntiDepressant Heart Attack Randomized Trial (SADHART) Platelet Substudy","volume":"108","author":"Serebruany","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.clinbiochem.2014.03.005_bb0520","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/0163-7258(96)00067-8","article-title":"Phenobarbital mechanistic data and risk assessment: enzyme induction, enhanced cell proliferation, and tumor promotion","volume":"71","author":"Whysner","year":"1996","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.clinbiochem.2014.03.005_bb0525","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1080\/00498250903098184","article-title":"Species differences in the hepatic effects of inducers of CYP2B and CYP4A subfamily forms: relationship to rodent liver tumour formation","volume":"39","author":"Lake","year":"2009","journal-title":"Xenobiotica"},{"key":"10.1016\/j.clinbiochem.2014.03.005_bb0530","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1093\/jnci\/djj188","article-title":"Statin use and breast cancer: prospective results from the Women's Health Initiative","volume":"98","author":"Cauley","year":"2006","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.clinbiochem.2014.03.005_bb0535","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.amjcard.2011.05.041","article-title":"Cardiovascular medications and risk of cancer","volume":"108","author":"Ocampo","year":"2011","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.clinbiochem.2014.03.005_bb0540","doi-asserted-by":"crossref","first-page":"e50893","DOI":"10.1371\/journal.pone.0050893","article-title":"Long-term use of angiotensin receptor blockers and the risk of cancer","volume":"7","author":"Azoulay","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.clinbiochem.2014.03.005_bb0545","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1111\/j.1365-2125.2012.04170.x","article-title":"Long term use of drugs affecting the renin\u2013angiotensin system and the risk of cancer: a population-based case\u2013control study","volume":"74","author":"Hallas","year":"2012","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.clinbiochem.2014.03.005_bb0550","first-page":"221","article-title":"Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in cancer progression and survival: a systematic review","volume":"23","author":"Mc Menamin","year":"2012","journal-title":"Cancer Causes Control"},{"key":"10.1016\/j.clinbiochem.2014.03.005_bb0555","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1016\/j.ijcard.2012.05.096","article-title":"Long-term use of angiotensin II receptor blockers and risk of cancer: a population-based cohort analysis","volume":"167","author":"Wang","year":"2013","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.clinbiochem.2014.03.005_bb0560","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1200\/JCO.2012.43.9190","article-title":"Use of \u03b2-blockers, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and risk of breast cancer recurrence: a Danish Nationwide Prospective Cohort Study","volume":"31","author":"S\u00f8rensen","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinbiochem.2014.03.005_bb0565","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.2146\/ajhp100570","article-title":"Risk of cancer associated with the use of angiotensin II-receptor blockers","volume":"68","author":"Olin","year":"2011","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.clinbiochem.2014.03.005_bb0570","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1160\/TH09-10-0695","article-title":"The TRITON versus PLATO trials: differences beyond platelet inhibition","volume":"103","author":"Serebruany","year":"2010","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.clinbiochem.2014.03.005_bb0575","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinbiochem.2014.03.005_bb0580","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1160\/TH09-07-0482","article-title":"Prasugrel compared with high-dose clopidogrel in acute coronary syndrome. The randomised, double-blind ACAPULCO study","volume":"103","author":"Montalescot","year":"2010","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.clinbiochem.2014.03.005_bb0585","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1056\/NEJMoa1308075","article-title":"Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes","volume":"369","author":"Montalescot","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinbiochem.2014.03.005_bb0590","doi-asserted-by":"crossref","first-page":"8","DOI":"10.2459\/JCM.0b013e328364561b","article-title":"Prasugrel and ticagrelor: is there a winner?","volume":"15","author":"Morici","year":"2014","journal-title":"J Cardiovasc Med (Hagerstown)"},{"key":"10.1016\/j.clinbiochem.2014.03.005_bb0595","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s12265-013-9527-3","volume":"7","author":"Schulz","year":"2014","journal-title":"J Cardiovasc Transl Res"}],"container-title":["Clinical Biochemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009912014001180?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009912014001180?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,14]],"date-time":"2025-09-14T15:42:23Z","timestamp":1757864543000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009912014001180"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5]]},"references-count":118,"journal-issue":{"issue":"7-8","published-print":{"date-parts":[[2014,5]]}},"alternative-id":["S0009912014001180"],"URL":"https:\/\/doi.org\/10.1016\/j.clinbiochem.2014.03.005","relation":{},"ISSN":["0009-9120"],"issn-type":[{"type":"print","value":"0009-9120"}],"subject":[],"published":{"date-parts":[[2014,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of prasugrel in acute coronary syndrome patients","name":"articletitle","label":"Article Title"},{"value":"Clinical Biochemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinbiochem.2014.03.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}